
Keywords: metastatic breast cancer; MBC; lobaplatin and gemcitabine; GL; lobaplatin and vinorelbine; NL; cisplatin and gemcitabine; GP; cisplatin and vinorelbine; NP; progression-free survival; PFS; overall survival; OS; response rate; RR; platinum-based compounds;